news
-
25 February 2021Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported results for the fourth quarter and fiscal year ended December 31, 2020.
Raymond W. Cohen, Axonics CEO, said, “In the first year of Axonics’ commercial launch in the United States, we exceeded our ambitious goals despite the pandemic and only having approximately ten months of selling time. We are grateful for the overwhelmingly positive response from physicians and patients to the introduction of our r-SNM System. We look forward to more Americans getting vaccinated and a return to a more normalized elective procedure environment in which we can take full advantage of the strong growth outlook for Axonics and the SNM market.”
Fourth Quarter 2020 Financial Results
Net revenue was $34.8 million in the fourth quarter 2020, as compared to net revenue of $9.9 million for the same period of the prior year. Net revenue was consistent with the preliminary revenue result Axonics previously reported in January. U.S. net revenue accounted for $33.7 million, with select international markets accounting for $1.1 million of net revenue.
Management estimates that in the fourth quarter 2020, approximately 320 confirmed and scheduled permanent implants were canceled due to COVID-19 based upon a detailed territory by territory analysis. These cancellations represented approximately $5 million of revenue that was not recognized in fourth quarter 2020. Management expects the majority of deferred cases to be rescheduled for the second half of 2021 as more individuals are vaccinated.
Gross margin was 63.6% in the fourth quarter 2020, as compared to 54.4% for the same period of the prior year.
Operating expenses were $33.0 million in the fourth quarter 2020, as compared to $28.1 million for the same period of the prior year.
Net loss was $11.3 million in the fourth quarter 2020, as compared to a net loss of $22.8 million for the same period of the prior year.
As of December 31, 2020, cash and cash equivalents were $241.2 million.
Fiscal Year 2020 Financial Results
Net revenue was $111.5 million in fiscal year 2020, as compared to net revenue of $13.8 million in fiscal year 2019. U.S. net revenue accounted for $107.5 million, with select international markets accounting for $4.0 million of net revenue.
Gross margin was 60.2% in fiscal year 2020, as compared to 53.0% in fiscal year 2019.
Operating expenses were $120.9 million in fiscal year 2020, as compared to $87.9 million in fiscal year 2019.
Net loss was $54.9 million in fiscal year 2020, as compared to a net loss of $79.9 million in fiscal year 2019.
Clinical and Regulatory Highlights
On October 5, 2020, Axonics published survey results of patients treated with the Axonics r-SNM System that were previously implanted with InterStim™ II.
On October 20, 2020, Axonics launched the ARTISTRY study, a post-market clinical registry following patients treated with the Axonics r-SNM System.
On October 29, 2020, Axonics announced the submission of a premarket approval supplement to the FDA for the purpose of gaining detachable extremity coil MRI conditional labeling for 1.5T and 3.0T MR scanners. The filing is currently under review by FDA.
On November 10, 2020, Axonics announced the publication of fecal incontinence study results for patients treated with its r-SNM System.
On January 28, 2021, a manuscript was published online in Neurourology and Urodynamics discussing the two-year outcomes of the ARTISAN-SNM study.
On February 16, 2021, Axonics announced FDA approval of its third-generation implantable neurostimulator.
Related
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2020 Revenue
Axonics® Provides Update on Inter Partes Review Proceedings
Axonics® Receives Health Canada Approval of Next Generation Implantable Neurostimulator
Axonics® Reports 2-Year Clinical Results from ARTISAN-SNM Pivotal Study
NICE Recommends Axonics® r-SNM System for Treating Overactive Bladder
Axonics® Reports Second Quarter 2020 Results
Axonics® Announces 2-Year Topline Clinical Results from ARTISAN-SNM Pivotal Study
Axonics® Reports Preliminary Second Quarter 2020 Revenue
Axonics® Receives FDA Approval for 3T Full-Body MRI Scans
Axonics® Reports First Quarter 2020 Results
Axonics® Announces Fourth Quarter and Fiscal 2019 Financial Results
Axonics® Sacral Neuromodulation System Receives Reimbursement Approval in Germany
Axonics® Announces FDA Approval of Enhanced Neurostimulator Programmer
Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems
Axonics® Announces Pricing of Public Offering of Common Stock
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of NICE Briefing
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axonics® Receives Health Canada Approval for its Sacral Neuromodulation External Trial System
Axonics® Announces Closing of Initial Public Offering of Common Stock
Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock
Axonics® Receives Technology Innovation Award from Medtech Insight
Axonics® Receives CE Mark for its Sacral Neuromodulation External Trial System
Axonics® Completes Enrollment of U.S. FDA Pivotal Study for its Sacral Neuromodulation System
Axonics Announces $40 Million Financing
Axonics® Sacral Neuromodulation System Receives Marketing Approval in Australia
Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer
Axonics Announces $20.5 Million Second Closing of its Series C Financing
Axonics Announces $14.5 Million First Close of Series C Financing
Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada
Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology
Axonics Sacral Neuromodulation System™ Receives MRI Conditional Labeling
Axonics Announces First Patients Treated in Sacral Neuromodulation Study
Axonics Granted Six U.S. Patents Related to its Implantable Neuromodulation Technology
Axonics Modulation Technologies Announces $38.5 Million Series B Financing